Back to results
US 2019/0290627 A1Published application
Pim kinase inhibitor combinations
AssigneeNovartis AG
InventorsZhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeNovartis AG
InventorsZhu Alexander Cao, Abdel Saci, K. Gary J. Vanasse, Joseph Daniel Growney
Estimating the term…
The present invention relates to a Pim kinase inhibitor compound that can be used alone or in a pharmaceutical combination. One such combination comprises (a) a JAK inhibitor compound, (b) a Pim kinase inhibitor compound, and optionally, at least one pharmaceutically acceptable carrier for simultaneous, separate or sequential use, in particular for the treatment of a myeloid neoplasm or leukemia; a pharmaceutical composition comprising such a combination; the use of such a combination for the preparation of a medicament for the treatment of myeloid neoplasm or leukemia; a commercial package or product comprising such a combination as a combined preparation for simultaneous, separate or sequential use; and to a method of treatment of a mammal, especially a human.
A pharmaceutical combination comprising ruxolitinib or a pharmaceutically acceptable salt therefore and N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (Compound A) or a pharmaceutically acceptable salt therefore.
A combination comprising N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (Compound A) and one or more of a targeted therapy drug, lenalidomide, thalidomide, pomalidomide, a protease inhibitor, bortezomib, carfilzomib, a corticosteroid, dexamethasone, prednisone, daratumumab, a chemotherapy drug, an anthracycline, doxorubicin, liposomal doxorubicin, melphalan, bisphosphonate, cyclophosphamide, etoposide, cisplation, carmustine, stem cell transplantation (bone marrow transplantation), radiation therapy or (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) (Compound B).
A combination comprising N-(4-((1R,3S,5S)-3-amino-5-methylcyclohexyl)pyridin-3-yl)-6-(2,6-difluorophenyl)-5-fluoropicolinamide (Compound A) and one or more of a targeted therapy drug, midostaurin, lenalidomide, thalidomide, pomalidomide, sorafenib, tipifamib, quizartinib, decitabine, a chemotherapy drug, decitabine, azacytidine, clofarabine, anthracycline, doxorubicin, liposomal doxorubicin, daunorubicin, idarubicin, cyatarbine, all-trans retonic acid (ATRA), arsenic trioxide, stem cell transplantation (bone marrow transplantation), radiation therapy or (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide).
An method of causing a PK exposure plateau to form comprising administered (S)-pyrrolidine-1,2-dicarboxylic acid 2-amide 1-({4-methyl-5-[2-(2,2,2-trifluoro-1,1-dimethyl-ethyl)-pyridin-4-yl]-thiazol-2-yl}-amide) in a dose of 200 mg to 350 mg.
Dependencies are inferred from the claim text.